Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease
Saleela M. Ruwanpura, Belinda J. Thomas, Philip G. Bardin
American Journal of Respiratory Cell and Molecular Biology (2020) Vol. 62, Iss. 4, pp. 413-422
Closed Access | Times Cited: 197

Showing 1-25 of 197 citing articles:

Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis
Jincheng Wang, Kaili Hu, Xuanyan Cai, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 1, pp. 18-32
Open Access | Times Cited: 249
Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
Qianru Mei, Zhe Liu, He Zuo, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 215
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
Paolo Spagnolo, Oliver Distler, Christopher J. Ryerson, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 2, pp. 143-150
Open Access | Times Cited: 175
Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis
Cristina Estornut, Javier Milara, María Amparo Bayarri, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 90
Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies
Isabella Lurje, Nadine T. Gaisa, Ralf Weiskirchen, et al.
Molecular Aspects of Medicine (2023) Vol. 92, pp. 101191-101191
Closed Access | Times Cited: 69
Localized Delivery of Healing Stimulator Medicines for Enhanced Wound Treatment
Mastafa H. Al-Musawi, S. Turki, Hanan Adnan Shaker Al-Naymi, et al.
Journal of Drug Delivery Science and Technology (2024), pp. 106212-106212
Closed Access | Times Cited: 16
Pirfenidone regulates seizures through the HMGB1/TLR4 axis to improve cognitive functions and modulate oxidative stress and neurotransmitters in PTZ-induced kindling in mice
Mansi Dahalia, Sparsh Gupta, Haya Majid, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access | Times Cited: 2
Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities
Izabela Tuleta, Nikolaos G. Frangogiannis
Advanced Drug Delivery Reviews (2021) Vol. 176, pp. 113904-113904
Open Access | Times Cited: 87
Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
Gabrielle Y. Liu, G. R. Scott Budinger, Jane E. Dematte
BMJ (2022), pp. e066354-e066354
Open Access | Times Cited: 67
TGF-β as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications
Jian Luo
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1206-1206
Open Access | Times Cited: 61
New progress in drugs treatment of diabetic kidney disease
Junmin Wang, Hongjiao Xiang, Yifei Lü, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 141, pp. 111918-111918
Open Access | Times Cited: 56
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
Alberto Aimo, Giosafat Spitaleri, Dario Nieri, et al.
Cardiac failure review (2022) Vol. 8
Open Access | Times Cited: 42
Pirfenidone ameliorates pulmonary inflammation and fibrosis in a rat silicosis model by inhibiting macrophage polarization and JAK2/STAT3 signaling pathways
Qiong Tang, Xing Chen, Ming Li, et al.
Ecotoxicology and Environmental Safety (2022) Vol. 244, pp. 114066-114066
Open Access | Times Cited: 39
Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies
Jorge Gutiérrez‐Cuevas, Silvia Lucano‐Landeros, Daniel López-Cifuentes, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 23-23
Open Access | Times Cited: 39
Application of Polymer Hydrogels in the Prevention of Postoperative Adhesion: A Review
Jie Cai, Jiaming Guo, Shige Wang
Gels (2023) Vol. 9, Iss. 2, pp. 98-98
Open Access | Times Cited: 35
Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery
Christine Shao, Nishant R. Sinha, Rajiv R. Mohan, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 657-657
Open Access | Times Cited: 29
Emerging role of immune cells as drivers of pulmonary fibrosis
Steven E. Mutsaers, Tylah Miles, Cecilia M. Prêle, et al.
Pharmacology & Therapeutics (2023) Vol. 252, pp. 108562-108562
Closed Access | Times Cited: 23
The gene expression of CALD1, CDH2, and POSTN in fibroblast are related to idiopathic pulmonary fibrosis
Shufei Wu, Mengying Liu, Mingrui Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 11
Pirfenidone ameliorates silica-induced lung inflammation and fibrosis in mice by inhibiting the secretion of interleukin-17A
Zhujie Cao, Ying Liu, Zhe Zhang, et al.
Acta Pharmacologica Sinica (2021) Vol. 43, Iss. 4, pp. 908-918
Open Access | Times Cited: 55
Molecular Mechanisms and Physiological Changes behind Benign Tracheal and Subglottic Stenosis in Adults
Alessandro Marchioni, Roberto Tonelli, Alessandro Andreani, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2421-2421
Open Access | Times Cited: 38
Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2
Samar A. Antar, Mohamed A. Saleh, Ahmed A. Al‐Karmalawy
Life Sciences (2022) Vol. 309, pp. 121048-121048
Open Access | Times Cited: 34
Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges
Ahmad Abu Qubo, Jamil Numan, Juan Snijder, et al.
Breathe (2022) Vol. 18, Iss. 4, pp. 220147-220147
Open Access | Times Cited: 34
TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis
Cheol Ho Park, Tae‐Hyun Yoo
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1485-1485
Open Access | Times Cited: 30
Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis
Lorraine Thong, Enda James McElduff, Michael T. Henry
Life (2023) Vol. 13, Iss. 2, pp. 486-486
Open Access | Times Cited: 22
Circadian clock molecule REV-ERBα regulates lung fibrotic progression through collagen stabilization
Qixin Wang, Isaac K. Sundar, Joseph H. Lucas, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top